New CEO takes over as Fujifilm Diosynth Biotechnologies expands 

Fujifilm Diosynth Biotechnologies in Texas
Fujifilm Diosynth Biotechnologies recently started a $35 million expansion of its biomanufacturing facility at its College Station, Texas site. (Fujifilm Diosynth Biotechnologies)

Fujifilm Diosynth Biotechnologies has named a new CEO who is, in fact, an old hand at the company. He takes over as the Japanese CDMO is in the midst of an infrastructure expansion in the U.S. 

Martin Meeson, currently president and chief operating officer of Fujifilm Diosynth Biotechnologies U.S.A becomes CEO April 1, taking over from Steve Bagshaw who will retire that position and become non-executive chairman, the company announced Monday.

RELATED: Fujifilm plans $20M U.S. facility for burgeoning interest in stem cell treatments  


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.

Meeson has held a variety of positions with the company since starting at Fujifilm Diosynth Biotechnologies (FDB) in 2008. He was first director of finance, IT and supply chain for its UK site and then became senior VP of global finance in 2013, working from the North Carolina site. He took on his current role in 2015. 

“Exciting times are ahead and the strength and energy of the people we have around us will continue to build our success as we move forward,” Meeson said in a statement. 

The planned transition comes as the company is in the midst of $120 million in capital projects for gene therapy production. Last week, it began operation of its new $21 million human induced pluripotent stem cells (iPSC) manufacturing facility. The 32,300-square-foot facility will provide capacity for FDB’s own regenerative products as well as operating as a CDMO for others working in the field. 

RELATED: Fujifilm pays Biogen nearly $1B for Denmark biologics site 

The company also recently started a $35 million expansion of its biomanufacturing facility at its College Station, Texas site to provide for late phase and commercial manufacturing of gene therapies and other advanced products. It already has an early-stage operation at the site.  

The company in August also struck an $890 million, all-cash deal for a Biogen biologics production facility in Denmark with about 800 employees. The 90,000-L capacity facility in Hillerød is the fourth biologics manufacturing site for Tokyo-based FDB, a partnership between Fujifilm and Mitsubishi.